0001104659-21-008348.txt : 20210128 0001104659-21-008348.hdr.sgml : 20210128 20210128060110 ACCESSION NUMBER: 0001104659-21-008348 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210128 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210128 DATE AS OF CHANGE: 20210128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp CENTRAL INDEX KEY: 0001082554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521984749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26301 FILM NUMBER: 21561900 BUSINESS ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 BUSINESS PHONE: 3016089292 MAIL ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 FORMER COMPANY: FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP DATE OF NAME CHANGE: 19990324 8-K 1 tm214459d1_8k.htm FORM 8-K
0001082554 false 0001082554 2021-01-28 2021-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  January 28, 2021

 

United Therapeutics Corporation

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   000-26301   52-1984749
(State or Other   (Commission   (I.R.S. Employer
Jurisdiction of   File Number)   Identification Number)
Incorporation)        

 

1040 Spring Street    
Silver Spring, MD   20910
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (301) 608-9292

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.01 per share   UTHR   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company      ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

 Item 8.01.  Other Events.

 

On January 28, 2021, United Therapeutics Corporation issued a press release announcing that the BREEZE and healthy volunteer pharmacokinetic studies of Tyvaso DPI™ met their primary objectives. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

TYVASO DPI is a trademark of United Therapeutics Corporation.

 

Item 9.01. Exhibits

 

 

(d)  Exhibits   
    
Exhibit No.  Description of Exhibit
    
99.1  Press release dated January 28, 2021
104  The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  UNITED THERAPEUTICS CORPORATION
     
     
Dated: January 28, 2021 By: /s/ Paul A. Mahon
  Name: Paul A. Mahon
  Title: General Counsel

 

 

 EX-99.1 2 tm214459d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

UNITED THERAPEUTICS ANNOUNCES BREEZE STUDY OF

INVESTIGATIONAL TYVASO DPI™ MEETS PRIMARY OBJECTIVE

 

Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning

from Tyvaso® Inhalation Solution

 

A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI

and Tyvaso Inhalation Solution

 

Tyvaso DPI NDA filing anticipated in April 2021 with priority review

 

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Thursday, January 28, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced today that that the BREEZE study of Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with pulmonary arterial hypertension (PAH) transitioning from Tyvaso (treprostinil) Inhalation Solution. In addition, a pharmacokinetic (PK) study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution.

 

Tyvaso DPI is a next-generation dry powder formulation of Tyvaso currently under development. If approved, Tyvaso DPI is expected to provide a more convenient method of administration as compared with traditional nebulized Tyvaso therapy.

 

“We are pleased with these results, which demonstrate the safety, tolerability, and pharmacokinetic profiles of treprostinil administered as Tyvaso DPI,” said Dr. Leigh Peterson, Vice President, Product Development at United Therapeutics. “We look forward to submitting our New Drug Application for Tyvaso DPI in April. If approved, we expect Tyvaso DPI will provide a major advancement in the delivery of inhaled treprostinil therapy, offering convenience benefits compared to our existing Tyvaso nebulizer.”

 

United Therapeutics intends to submit a New Drug Application (NDA) to the FDA for Tyvaso DPI for indications covering PAH and pulmonary hypertension associated with interstitial lung disease in April 2021 and plans to apply a priority review voucher to the Tyvaso DPI NDA, providing an expedited FDA review period.

 

The BREEZE study demonstrated safety and tolerability of Tyvaso DPI in subjects with PAH transitioning from Tyvaso Inhalation Solution

 

The BREEZE study was a single-sequence study in which 51 subjects on a stable regimen of Tyvaso Inhalation Solution were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution.

 

Secondary objectives of the study were to evaluate: (1) the systemic exposure and pharmacokinetics of treprostinil when delivered as Tyvaso Inhalation Solution and Tyvaso DPI; (2) six-minute walk distance (6MWD) at study entry and after three weeks of treatment with Tyvaso DPI; (3) the long-term safety and tolerability of Tyvaso DPI during an optional extension phase (OEP) in patients previously treated with Tyvaso Inhalation Solution; (4) patient satisfaction with and preference for inhaled treprostinil devices assessed at study entry when patients were using Tyvaso Inhalation Solution and after three weeks using Tyvaso DPI; and (5) patient-reported PAH symptoms and impact (PAH-SYMPACT®) assessed at study entry when patients were using Tyvaso Inhalation Solution and after three weeks using Tyvaso DPI.

 

 

 

 

Primary safety and tolerability objective. Transition from Tyvaso Inhalation Solution to Tyvaso DPI was safe and well tolerated. Forty-nine out of 51 patients (96%) completed the treatment phase and there were no study drug related adverse events. Most adverse events experienced during the study were mild to moderate in severity and occurred at severities and frequencies consistent with those seen in other inhaled treprostinil studies in patients with PAH.

 

Secondary objectives. Three weeks after switching from Tyvaso Inhalation Solution to Tyvaso DPI, patients in the BREEZE study demonstrated:

 

·Improvements in 6MWD compared to baseline. These improvements in 6MWD compared to baseline were sustained in the OEP through the data cut-off date.

 

·Improvements in overall satisfaction with the Tyvaso DPI inhaler compared to the Tyvaso Inhalation Solution nebulizer at baseline using an internally developed satisfaction and preference questionnaire.

 

·Improvement in patient-reported outcomes using the validated PAH-SYMPACT questionnaire.

 

Optional extension phase. Subjects in BREEZE were given the opportunity to continue in an OEP. All subjects who completed the treatment phase (49/51) elected to continue in the OEP.

 

PK data collected during the BREEZE study are currently undergoing final analysis. Detailed data from the BREEZE study will be presented in upcoming publications and scientific conferences.

 

Tyvaso DPI demonstrated comparable treprostinil exposure to Tyvaso Inhalation Solution in healthy volunteers

 

The healthy volunteer PK study was a randomized six-period, six-sequence crossover study of three dose levels of Tyvaso DPI and three dose levels of Tyvaso Inhalation Solution in 36 healthy volunteers. The primary objective of the study was to evaluate the systemic exposure and PK of treprostinil administered as Tyvaso DPI and Tyvaso Inhalation Solution. Secondary objectives of the study evaluated the safety and tolerability of Tyvaso DPI.

 

Study results. Subjects demonstrated comparable systemic treprostinil exposure for each corresponding Tyvaso DPI and Tyvaso Inhalation Solution dose level. Between-subject variability for both AUC0-5h and Cmax was approximately 50% less for Tyvaso DPI compared to Tyvaso Inhalation Solution, suggesting a more precise dosing profile for Tyvaso DPI relative to nebulized Tyvaso.

 

Safety. The adverse event profile for Tyvaso DPI in healthy volunteers was consistent with known prostacyclin effects and previous studies of Tyvaso Inhalation Solution.

 

Detailed data from the healthy volunteer PK study will be presented in upcoming publications and scientific conferences.

 

About Tyvaso DPI

 

Tyvaso DPI™, previously referred to as Treprostinil Technosphere®, is an investigational drug-device combination therapy comprised of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso® therapy. United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation. Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat® inhalation device technology used in MannKind’s Afrezza® (insulin human) Inhalation Powder product, which was approved by the FDA in 2014.

 

United Therapeutics plans to submit the Tyvaso DPI NDA with an indication to treat pulmonary arterial hypertension (PAH), as well as pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso is indicated to treat World Health Organization (WHO) Group 1 PAH, and the FDA is currently reviewing a supplement to the Tyvaso NDA to reflect the results of the INCREASE study and expand its labeling to include PH-ILD.

 

2 

 

 

Tyvaso DPI is an investigational combination product that is not approved for any use in any country, and the Tyvaso DPI tradename is pending final FDA review.

 

About TYVASO® (treprostinil) Inhalation Solution

 

INDICATION

 

TYVASO (treprostinil) is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

 

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

 

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

 

IMPORTANT SAFETY INFORMATION FOR TYVASO

 

WARNINGS AND PRECAUTIONS

 

·The efficacy of TYVASO has not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease). Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect

 

·TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may cause symptomatic hypotension

 

·Titrate slowly in patients with hepatic or renal insufficiency, as exposure to treprostinil may be increased in these patients

 

·TYVASO inhibits platelet aggregation and increases the risk of bleeding

 

·Co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil may increase exposure to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events, whereas decreased exposure is likely to reduce clinical effectiveness

 

DRUG INTERACTIONS/SPECIFIC POPULATIONS

 

·The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension

 

·Co-administration of the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to oral treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to oral treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8

 

·Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production

 

·Safety and effectiveness in pediatric patients have not been established

 

·It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients

 

3 

 

 

ADVERSE REACTIONS

 

 ·

The most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥10% of patients were dizziness and diarrhea

 

Please see the Full Prescribing Information, Patient Product Information, and the TD-100 and TD-300 TYVASO® Inhalation System Instructions for Use manuals. For additional information about TYVASO, visit www.tyvaso.com or call 1-877-UNITHER (1-877-864-8437).

 

For Consumer Important Safety Information, please see https://www.tyvaso.com/dtc/isi


About United Therapeutics

 

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.

 

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

 


Forward-looking Statements

 

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to the anticipated timing and outcome of the New Drug Application for Tyvaso DPI and our pending supplemental New Drug Application for Tyvaso to update its labeling to include a PH-ILD indication, the potential indications for Tyvaso DPI, the expected benefits of Tyvaso DPI to patients, our plan to seek both PAH and PH-ILD indications when we submit our Tyvaso DPI NDA, our expectation that Tyvaso DPI will represent a major advancement in the delivery of inhaled treprostinil therapy, our commitment to bring a new generation of treatments to patients with PAH, and the timing thereof, our ability to create value and sustain our success in the long term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of January 28, 2021 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

 

TYVASO is a registered trademark of United Therapeutics Corporation.

TYVASO DPI is a trademark of United Therapeutics Corporation.

 

AFREZZA, DREAMBOAT, and TECHNOSPHERE are registered trademarks of MannKind Corporation.

 

PAH-SYMPACT is a registered trademark of Actelion Pharmaceuticals Ltd société anonyme.

 

For Further Information Contact:

Dewey Steadman at (202) 919-4097

Email: ir@unither.com

 

*          *         *

4 

 

 EX-101.SCH 3 uthr-20210128.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 uthr-20210128_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 uthr-20210128_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm214459d1_ex99-1img001.jpg GRAPHIC begin 644 tm214459d1_ex99-1img001.jpg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end XML 7 tm214459d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001082554 2021-01-28 2021-01-28 iso4217:USD shares iso4217:USD shares 0001082554 false 8-K 2021-01-28 United Therapeutics Corporation DE 000-26301 52-1984749 1040 Spring Street Silver Spring MD 20910 301 608-9292 false false false false Common Stock, par value $0.01 per share UTHR NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Jan. 28, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 28, 2021
Entity File Number 000-26301
Entity Registrant Name United Therapeutics Corporation
Entity Central Index Key 0001082554
Entity Tax Identification Number 52-1984749
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1040 Spring Street
Entity Address, City or Town Silver Spring
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20910
City Area Code 301
Local Phone Number 608-9292
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol UTHR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://unither.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm214459d1_8k.htm tm214459d1_ex99-1.htm uthr-20210128.xsd uthr-20210128_lab.xml uthr-20210128_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm214459d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm214459d1_8k.htm" ] }, "labelLink": { "local": [ "uthr-20210128_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "uthr-20210128_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "uthr-20210128.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uthr", "nsuri": "http://unither.com/20210128", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm214459d1_8k.htm", "contextRef": "From2021-01-28to2021-01-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://unither.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm214459d1_8k.htm", "contextRef": "From2021-01-28to2021-01-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unither.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-008348-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-008348-xbrl.zip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end